Escolar Documentos
Profissional Documentos
Cultura Documentos
• TB usually affects
the lungs (80% of
cases) but can
affect any part of
an infected person
AERAS GLOBAL TB VACCINE FOUNDATION
The TB Pandemic
• The World Health Organization (WHO)
estimates that in 2008:
– 9.4 million new cases of TB were
diagnosed
– 1.8 million people died from TB
No estimate
0-24
25-49
50-99
100-299
>= 300
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health
Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
WHO 2009. All rights reserved
AERAS GLOBAL TB VACCINE FOUNDATION
The TB Pandemic
• TB is the world’s 2nd most deadly infectious disease in
adults, after HIV/AIDS, and one of leading causes of
death globally.
HIV prevalence in
TB cases, (%)
No estimate
0–4
5–19
20–49 The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health
Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
>= 50 Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
WHO 2009. All rights reserved
AERAS GLOBAL TB VACCINE FOUNDATION
deaths is linked to TB
HIV/AIDS and TB:
A Deadly Combination
TB/HIV Co-infection
• TB is the leading cause of death PLWHA in Africa and a
major cause elsewhere
+
AERAS GLOBAL TB VACCINE FOUNDATION
TB Drug Resistance
• WHO estimates 490,000 MDR-TB cases emerge every
year, with more than 110,000 deaths
• Market uncertainty
Diagnostics Pipeline
T
DS i al
e& erc ds
tur m
m etho
cul -co
p id Nonture m
Ra id on cul
Rapeciati
sp
First Referral Level 10-40%
*
D S T) NAAST)
T DST
AT ( v ed y
te d D etri c
% Access after 5
pro op
years
A a & ri m
lN Im icrosc Automction d colo l NAAT
an ua te p i a *
M m (de Ra Manu tion)*
te c
(de Peripheral Lab 70%
Distance from
est ) e AT
C t ion ictiv l NA
PO etect d
Patients
a
Pre I anu tion)
(d
LTBM etec
Community Health (d 95%
***
Care
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Technologies in boxes: endorsed by
WHO
Abbreviations * Manual NAAT: technology for MTB Drug Susceptibility Testing (Line Probe Ass
DST: Drug Susceptibility Test
* * Manual NAAT: technology for MTB detection at the Peripheral Lab
NAAT: Nucleic Acid * * * Manual NAAT: technology for MTB detection at the Community Health Care L
Amplification Test
LTBI: Latent TB Infection
POC: Point of Care
AERAS GLOBAL TB VACCINE FOUNDATION
Oflotub,
TDR
Bayer,
TB Alliance
J&J/Tibotec
Otsuka
Lupin
TB Alliance
Sequella
Pfizer
Korea
China (3)
Delhi Taiwan
Mexico
Hong Kong
Malaysia Thailand (3)
Kenya
Tanzania (2)
Peru
Zambia
AERAS402/Crucell Ad35
Crucell N.V./Aeras
MVA85A/AERAS-485
ing Group on New TB Vaccines
OETC/Aeras
Additional research at the discovery/early pre-clinical level: Bhagawan Mahavir Medical Research Center; Cardiff University; EpiVax, Inc.; ImmunoBiology Ltd.; Infectious Disease Research
Institute; Institute de Pharamacologie, Puso; Karolinska Institute; Malaysia-Finlay Institute, NIAID; NIH; Osaka University; Shanghai H&G Biotech; Sequella; UCLA; and, Vanderbilt University.
/UCT, South Africa
KEMRI/CDC, Kenya
St John’s
Centre
anhica Health ResearchResearch
Mozambique Institute, India
Cambodian Health
Committee, Cambodia
AERAS GLOBAL TB VACCINE FOUNDATION
Method
• Collaborate with academic, biotech,
pharmaceutical and NGO partners to
develop and test new TB vaccines
• Purse a Prime-Boost strategy by
developing a modern replacement for
BCG plus booster vaccines
• Develop vaccines in its own lab and
manufacturing plant
AERAS GLOBAL TB VACCINE FOUNDATION
• Prime-Boost regimen
Summary
• New TB vaccines, drugs and diagnostics
– will help achieve global development goals
– are critical to controlling TB pandemic
– will reduce the cost and burden of TB on patients, health care
systems and national economies
• PDPs are leading the effort to develop new TB tools that will be
affordable and accessible worldwide, engaging stakeholders from across
sectors toward common goals
• Research collaborations in TB endemic countries build and strengthen
research capacity, and are critical to advancing product candidates
• New tools need to be a global priority to help ensure rapid development
and distribution
AERAS GLOBAL TB VACCINE FOUNDATION